REG - Redx Pharma plc - Notice of AGM

Redx PharmaAnnouncement

15/02/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230215:nRSO0599Qa&default-theme=true

RNS Number : 0599Q  Redx Pharma plc  15 February 2023

REDX PHARMA PLC

("Redx" or "the Company")

 

Notice of Annual General Meeting

 

Alderley Park, 15 February 2023 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, today announces that its Annual General Meeting will be held
at 11am on 14 March 2023 at the offices of Cooley (UK) LLP, 22 Bishopsgate,
London EC2N 4BQ.

 

Following the announcement of preliminary results for the financial year ended
30 September 2022 on 20 December 2022, the Company announces that the Annual
Report and Accounts and notice of Annual General Meeting have now been posted
to shareholders. The Annual Report and Accounts and notice of Annual General
Meeting are also available to view on Redx's website at www.redxpharma.com
(http://www.redxpharma.com/) .

 

Shareholders are strongly encouraged to vote by proxy, appointing the Chair of
the meeting, using the form of proxy distributed with the notice of meeting,
to ensure their vote counts. The form of proxy is also available in the
investor resources section of the Company's website: www.redxpharma.com
(http://www.redxpharma.com/)

 

Completed proxies should be returned to:

 

Equiniti

Aspect House

Spencer Road

Lancing

BN99 6DA

 

and must be received by 11am on 10 March 2023 to be valid.

 

 

 For further information, please contact:

 Redx Pharma Plc                                     T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)         T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes
 WG Partners LLP (Joint Broker)                      T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)          T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                      T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases and the
emerging area of cancer-associated fibrosis, aiming initially to progress them
to clinical proof of concept before evaluating options for further development
and potential value creation. Redx's lead oncology product candidate, the
Porcupine inhibitor RXC004, being developed as a targeted treatment for
Wnt-ligand dependent cancers, commenced a Phase 2 programme in November 2021.
The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor
RXC007, is in development for interstitial lung disease and commenced a Phase
2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022. Redx's third
drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of
fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at
the end of 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult
patients with mantle cell lymphoma previously treated with a covalent BTK
inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic
diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical
study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now
progressing through Phase 1 clinical studies and an early stage oncology
research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGPURWPUPWGQA